Published April 7, 2022 By Vanessa Doctor, RN BioSpace Shares in Acadia Pharmaceuticals rose 5.71% to $27.22 per share at the close of NASDAQ Wednesday on positive late-stage data from the study […]

Acadia Pharmaceuticals Inc. and Neuren Pharmaceuticals Limited announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.